## GILD: Gilead Sciences, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.6% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($115.42)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Redeye: Sprint Bioscience (Q3 review) - Gilead deal a strong confirmation**
- Source: TradingView | 20251205T080940 | Bullish | Relevance: 99%
-  Redeye has provided an update on Sprint Bioscience following its Q3 report, highlighting the positive impact of selling the TREX1 program to Gilead Sciences. The company now has a robust cash position, allowing it to further develop internal programs and business development activities. Redeye has raised its base case for Sprint Bioscience.

**2. Amundi Purchases 1,614,355 Shares of Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251205T091158 | Bullish | Relevance: 98%
-  Amundi recently increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 18.2%, acquiring an additional 1,614,355 shares, bringing its total holdings to over 10.4 million shares valued at $1.16 billion. Other institutional investors like Vanguard Group and Geode Capital Management also adjusted their positions. Analysts maintain a "Moderate Buy" rating with an average target price of $130.65 for Gilead Sciences.

**3. Channing Capital Management LLC Purchases 43,875 Shares of Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251204T101109 | Somewhat-Bullish | Relevance: 98%
-  Channing Capital Management LLC significantly increased its stake in Gilead Sciences, Inc. by purchasing 43,875 additional shares, bringing their total holdings to 101,884 shares valued at $11,296,000. This comes amidst other institutional investors modifying their positions and analysts setting new price targets for GILD. The article also details Gilead Sciences' recent financial performance, upcoming dividend, and insider trading activity.

**4. Gilead Sciences (GILD) Stock Outlook: Mizuho Lifts Target Amid Stronger Biktarvy Timeline**
- Source: MSN | 20251204T091041 | Bullish | Relevance: 98%
- Mizuho has increased its price target for Gilead Sciences (GILD) after a recent KOL event clarified the Biktarvy timeline, suggesting potential for stronger mid-decade revenue. The analyst anticipates continued growth for Biktarvy, driven by its effective and tolerable profile in the HIV market. Despite competitive pressures, Gilead's robust pipeline and strategic focus are expected to support its long-term market position.

**5. Gilead Sciences, Inc. $GILD Shares Acquired by Guggenheim Capital LLC**
- Source: MarketBeat | 20251204T100754 | Somewhat-Bullish | Relevance: 97%
-  Guggenheim Capital LLC increased its stake in Gilead Sciences, Inc. by 5.6% during the second quarter, now holding 560,937 shares valued at $62.19 million. The biopharmaceutical company recently beat quarterly EPS and revenue estimates and announced a quarterly dividend of $0.79 per share. Despite some insider selling, analysts maintain a "Moderate Buy" consensus rating for GILD.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | Needham | $140 | $133 | +5% |
| 2025-11-13 | Scotiabank | $140 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | Needham | main | Buy |
| 2025-11-13 | Scotiabank | init | Sector Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($10.00M) |
| Sells | 14 ($7.11M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (-0.3%)
- Blackrock Inc.: 9.4% (+1.2%)
- FMR, LLC: 4.9% (+0.6%)
- State Street Corpora: 4.8% (-0.2%)
- Capital World Invest: 3.6% (-2.4%)

### Key Risks

1. Insider selling cluster: $7.1M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.21 indicates undervaluation relative to growth. Forward P/E 13.9x stretched relative to 7% growth. Quality metrics strong (ROE 41%, ROA 13%, margin 28%). Balance sheet: $4.0B free cash flow. Analyst sentiment positive (1 raises, avg +5%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $148.1B |
| Beta | 0.33 |
| 52W Range | $88.57 - $128.70 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.21 |
| Forward P/E | 13.9 |
| Current P/E | 14.8 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -3.5% to -4.6% (-1.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.6pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.07x) but short-term weakness (below SMA20). MACD histogram bearish (-0.71), momentum weakening. RSI neutral at 45.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.59% (CS: 9) | Weak |
| RSI_14 | 44.6 | Neutral |
| MACD Histogram | -0.71 | Bearish |
| vs SMA20 | 0.975x | Below |
| vs SMA50 | 1.005x | Above |
| vs SMA200 | 1.073x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $121.22
- **Stop Loss:** $115.42 (4.8% risk)
- **Target:** $127.02 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 86
- **Position Value:** $10,424.92
- **Portfolio %:** 10.42%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-10 (Est: $1.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.14 | $2.47 | +15.7% |
| 2025Q2 | $1.96 | $2.01 | +2.7% |
| 2025Q1 | $1.78 | $1.81 | +1.9% |
| 2024Q4 | $1.70 | $1.90 | +11.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*